Overview

Vancomycin for Primary Sclerosing Cholangitis

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Arizona State University
Elizabeth Carey
Collaborators:
Arizona State University
Mayo Clinic
University of Calgary
Treatments:
Vancomycin